- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07604207
Multi-organ Imaging of Microvascular and Metabolic Function
May 18, 2026 updated by: Kevin, Chung, Massachusetts General Hospital
What if heart disease starts outside the heart?
This research will study how to simultaneously assess brain and body physiology, how they are jointly related to heart function, and how their response to physical and mental stress differs in patients with heart disease.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kevin J. Chung, PhD
- Phone Number: 617-724-9232
- Email: kchung0@mgh.harvard.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Adults aged 18 years and older
- For patients with cardiovascular disease: Documented diagnosis of ischemic heart disease based on standard clinical, radiologic, and/or histopathologic criteria, as documented in the medical record; or a clinical nuclear cardiac stress PET test within 1 year.
- For healthy subjects: No diagnosis of cardiometabolic disease, cancer, or other major disease within the past 5 years
Exclusion Criteria:
Contraindications to PET due to:
- Research-related radiation exposure exceeding current MGB Radiology Department guidelines (i.e., 50 mSv in the prior 12 months);
- Inability to lie comfortably on the bed inside the scanner;
- Body weight > 300 lbs (weight limit of the scanner table);
- Pregnancy or breastfeeding;
- Individuals with fasting plasma glucose level of >200 mg/dL;
- Claustrophobia
- Employed under the direct supervision of the PI conducting the research.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Dynamic PET/CT scan
Each subject will undergo one or more dynamic PET/CT scans with various acute stressors
|
Dynamic 18F-FDG PET
Panorama GS PET/CT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood flow responses
Time Frame: During the procedure
|
The primary endpoint is to evaluate if blood flow responses to acute stressors can be quantitatively measured with 18F-FDG
|
During the procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose metabolism responses
Time Frame: During the scan
|
The secondary endpoint is to evaluate if glucose metabolic responses to acute stressors can be quantitatively measured with 18F-FDG
|
During the scan
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2026
Primary Completion (Estimated)
July 1, 2031
Study Completion (Estimated)
July 1, 2031
Study Registration Dates
First Submitted
May 18, 2026
First Submitted That Met QC Criteria
May 18, 2026
First Posted (Actual)
May 22, 2026
Study Record Updates
Last Update Posted (Actual)
May 22, 2026
Last Update Submitted That Met QC Criteria
May 18, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Diagnostic Techniques and Procedures
- Diagnosis
- Carbohydrates
- Tomography
- Diagnostic Imaging
- Deoxyglucose
- Deoxy Sugars
- Image Interpretation, Computer-Assisted
- Image Enhancement
- Photography
- Tomography, Emission-Computed
- Radionuclide Imaging
- Diagnostic Techniques, Radioisotope
- Fluorodeoxyglucose F18
- Positron-Emission Tomography
Other Study ID Numbers
- 2026P001016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects (HS)
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Not yet recruitingHealthy Subjects (HS)
-
Shenyang Sunshine Pharmaceutical Co., LTD.Not yet recruitingHealthy Subjects (HS)
-
University of ManchesterRecruitingHealthy Subjects (HS)United Kingdom
-
Biotech Pharmaceutical Co., Ltd.Not yet recruitingHealthy Subjects (HS)
-
University of VigoNot yet recruiting
-
Otsuka Beijing Research InstituteOtsuka Pharmaceutical Development & Commercialization, Inc.CompletedHealthy Subjects (HS)China
-
Youngstown State UniversityRecruiting
-
The Hong Kong Polytechnic UniversityRecruiting
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Recruiting
-
WockhardtCovanceCompletedHealthy Subjects (HS)United States
Clinical Trials on 18F-FDG
-
Affiliated Hospital of Jiangnan UniversityRecruitingPositron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor EfficacySolid Tumor | Breast Cancer Stage II | Breast Cancer Stage IIIChina
-
Turku University HospitalCompleted
-
Tim LauMcGill UniversityNot yet recruitingCognitive Impairment | Dementia | Dementia With Lewy Bodies
-
Asan Medical CenterCompletedColorectal CancerKorea, Republic of
-
Ottawa Heart Institute Research CorporationNot yet recruitingPericarditis
-
University of AdelaideCentral Adelaide Local Health Network IncorporatedCompletedInflammation | Fever | Fever of Unknown Origin | Inflammation of Unknown OriginAustralia
-
Avid RadiopharmaceuticalsCompletedFrontotemporal Dementia | Alzheimer's DiseaseUnited Kingdom
-
Rigshospitalet, DenmarkCopenhagen University Hospital at HerlevRecruitingDiabete Type 2 | Alzheimer Dementia (AD)Denmark
-
First Hospital of China Medical UniversityRecruiting
-
Stanford UniversityWithdrawn